Von Eschenbach attacked from both sides
This article was originally published in The Gray Sheet
Executive Summary
Conservatives, including Concerned Women for America and the National Pro-Life Action Center, call for the withdrawal of FDA Acting Commissioner Andrew von Eschenbach's nomination to head the agency in reaction to FDA signals that it might be moving toward approving over-the-counter status for Barr Pharmaceutical's Plan B emergency contraceptive. The firm plans to resubmit its OTC application by the end of the month after an Aug. 8 meeting with the agency. Meanwhile, Sens. Hilary Clinton (D-N.Y.) and Patty Murray (D-Wash.), who support the OTC switch, said July 31 they will maintain their hold on von Eschenbach's nomination until the agency makes a decision (1"The Gray Sheet" Aug. 7, 2006, p. 17)...
You may also be interested in...
Von Eschenbach Nomination Still Stalled After Some Movement On Plan B
Senators Hilary Rodham Clinton (D-N.Y.) and Patty Murray (D-Wash.) will maintain their hold on Andrew von Eschenbach's nomination to head FDA, despite what von Eschenbach calls an "important decision" regarding Barr Laboratories' application to offer its Plan B emergency contraceptive over the counter (OTC)
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.